The lidERA Breast Cancer study is a phase 3, randomized, open-label trial testing whether the adjuvant therapy giredestrant ...

HR+/HER2- breast cancer—or hormone receptor-positive, HER2-negative breast cancer—is the most common subtype of breast cancer. It makes up about 70% of all breast cancer cases. HR+/HER2- breast cancer ...

Breast cancer is a complex disease with many types. Understanding the specific type and classification of the breast cancer you have is crucial so that you can fully participate as an informed partner ...

One in eight women in the U.S. will be diagnosed with breast cancer in their lifetime. For many, the diagnosis doesn’t end ...

Cancer treatment is so much more exciting now than it was even 5 or 10 years ago, because not only are treatments so much better, but they're so much easier to take. The stage of cancer is one of the ...

Giredestrant significantly improves IDFS in ER-positive, HER2-negative early-stage breast cancer, surpassing standard ...

Topline data were announced from a phase 3 trial evaluating giredestrant for the adjuvant treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ...

A diagnosis of triple-negative breast cancer is typically made after a biopsy confirms the tumor’s receptor status. Imaging ...

Normally, HER2 helps your healthy breast cells grow and divide. But too much HER2 can trigger cells to grow out of control. HER2-positive breast cancer happens when the HER2 gene in your DNA mutates ...

If you have HER2-positive breast cancer, your options for treatment will depend on several factors, such as the stage of cancer (early or metastatic) and the hormone receptor status of the tumor. HER2 ...

Three years after striking up a Zymeworks licensing pact with an eye on challenging the status quo in HER2-positive cancers, ...